Trial record 47 of 138 for:    johnstown

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA-TIMI)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT02019264
First received: December 18, 2013
Last updated: July 15, 2016
Last verified: July 2016
  Purpose
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors.

Condition Intervention Phase
Cardiovascular Disease
High Cardiovascular Risk
Obesity
Overweight
Type 2 Diabetes
Drug: APD356-Lorcaserin hydrochloride
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Resource links provided by NLM:


Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • Time from randomization to first occurrence of Major Adverse Cardiovascular Events (MACE) [ Time Frame: Up to 5 years ] [ Designated as safety issue: Yes ]
    MACE events include: myocardial infarction, stroke and cardiovascular (CV) death

  • Time from randomization to conversion to type 2 diabetes mellitus (T2DM) for subjects without any type of diabetes at Baseline [ Time Frame: Baseline, and specified timepoints up to 5 years ] [ Designated as safety issue: No ]
  • Time from randomization to first occurrence of MACE+ [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    MACE+ events include: myocardial infarction, stroke, CV death, and hospitalization due to unstable angina, heart failure, or any coronary revascularization


Secondary Outcome Measures:
  • Time from randomization to event of each component of MACE+ [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Time from randomization to event of all-cause mortality [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Time from randomization to event of new onset renal impairment or worsening existing renal impairment in subjects with T2DM at Baseline [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    New onset renal impairment or worsening existing renal impairment include the first occurrence of microalbuminuria, macroalbuminuria, worsening of albuminuria, newly developed CKD, or worsening of CKD, doubling of serum creatinine, or any of the following: ESRD, renal transplant, and renal death.

  • Time from randomization to event of improvement in renal function [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Change from Baseline in HbA[1c] at 6 months in subjects with T2DM at Baseline [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
  • The proportion of subjects who meet FDA-defined valvulopathy in echocardiographically determined heart valve changes [ Time Frame: Baseline and 1 year ] [ Designated as safety issue: Yes ]
    Comparison between lorcaserin HCl and placebo will be made at 1 year.

  • The percent change from Baseline in echocardiographically-determined pulmonary arterial systolic pressure [ Time Frame: Baseline and 1 year ] [ Designated as safety issue: Yes ]
    Comparison between lorcaserin HCl and placebo will be made at 1 year.

  • Time to conversion to normal glucose homeostasis [ Time Frame: Baseline and 1 year ] [ Designated as safety issue: No ]

Enrollment: 12000
Study Start Date: January 2014
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: APD356 10 mg
APD356 10 mg twice daily
Drug: APD356-Lorcaserin hydrochloride
APD356 10 mg twice daily
Placebo Comparator: Placebo
Placebo twice daily
Drug: Placebo
Placebo twice daily

Detailed Description:
Approximately 12,000 subjects will be randomized to two treatment groups in a ratio of 1:1, stratified by the presence of established CV disease (approximately 80%) or CV risk factors without established CV disease (approximately 20%). Subjects will receive lorcaserin HCl 10 mg BID or placebo BID. The study will consist of 2 phases: Prerandomization and Randomization. The Prerandomization Phase will last up to 30 days and consist of one visit during which subjects will be screened for eligibility. The Randomization Phase will consist of two periods: Treatment and Follow-up. The Treatment Period will last for approximately 5 years with approximately 18 visits and Follow-up period is 30 (+ or - 10 days) from the end of treatment visit.
  Eligibility

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. BMI greater than or equal to 27 kg/m^2
  2. Subjects able and willing to comply with a reduced-calorie diet and an increased physical activity program
  3. Age greater than or equal to 40 years with established CV disease as defined by one of the following:

    1. History of documented MI or ischemic stroke
    2. History of peripheral artery disease
    3. History of revascularization (coronary, carotid, or peripheral artery)
    4. Significant unrevascularized coronary arterial stenosis

OR

Age greater than or equal to 55 years for women or greater than or equal to 50 years for men who have T2DM without established CV disease plus at least one of the following CV risk factors:

  1. Hypertension, or currently receiving therapy for documented hypertension
  2. Dyslipidemia, or currently taking prescription lipid-lowering therapy for documented dyslipidemia
  3. Calculated creatinine clearance greater than or equal to 30 to less than or equal to 60 mL/min per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
  4. High hsCRP
  5. Urinary albumin-to-creatinine ratio (ACR) greater than or equal to 30 ug/mg

Subjects with T2DM may have a pre-existing or new diagnosis of T2DM. A new diagnosis of T2DM (ie, discovered at Screening) should be based on the 2013 American Diabetes Association (ADA) guidelines.

All T2DM subjects must have an HbA[1c] less than 10% at Screening. If subjects are being treated, or upon diagnosis need to be treated with antidiabetic agents, the T2DM treatment regimen must be stable for at least 3 months prior to randomization.

Exclusion Criteria

  1. Moderate or greater symptoms of congestive cardiac failure (New York Heart Association [NYHA] class III or IV)
  2. Known left ventricular (LV) ejection fraction less than 20%
  3. Moderate or greater symptoms of pulmonary hypertension (PH)
  4. Known severe valvular disease Moderate renal impairment, severe renal impairment, or end stage renal disease (ESRD) (calculated creatinine clearance less than 30 mL/min per the CKD-EPI equation based on ideal body weight)
  5. Severe hepatic impairment
  6. Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations
  7. Use of more than one other serotonergic drug
  8. Use of drugs known to increase the risk for cardiac valvulopathy prior to Screening including, but not limited to: cyproheptadine, amoxapine, TCAs, mirtazapine, pergolide, ergotamine, methysergide, cabergoline
  9. History or evidence of clinically significant disease (e.g., malignancy, cardiac, respiratory, gastrointestinal, renal or psychiatric disease)
  10. Use of lorcaserin HCl prior to Screening or hypersensitivity to lorcaserin HCl or any of the excipients
  11. Planned bariatric surgery
  12. Females must not be breastfeeding or pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02019264

  Hide Study Locations
Locations
United States, Alabama
Alexander City, Alabama, United States
Athens, Alabama, United States
Birmingham, Alabama, United States
Mobile, Alabama, United States
United States, Alaska
Anchorage, Alaska, United States
United States, Arizona
Chandler, Arizona, United States
Glendale, Arizona, United States
Tucson, Arizona, United States
United States, Arkansas
Jonesboro, Arkansas, United States
Little Rock, Arkansas, United States
United States, California
Alhambra, California, United States
Bakersfield, California, United States
Beverly Hills, California, United States
Carmichael, California, United States
Chula Vista, California, United States
Concord, California, United States
Encino, California, United States
Greenbrae, California, United States
Huntington Beach, California, United States
Huntington Park, California, United States
La Mesa, California, United States
Laguna Hills, California, United States
Lomita, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Mission Viejo, California, United States
Murrieta, California, United States
Northridge, California, United States
Oceanside, California, United States
Redding, California, United States
San Diego, California, United States
San Ramon, California, United States
Santa Ana, California, United States
Thousand Oaks, California, United States
Torrance, California, United States
Ventura, California, United States
West Hills, California, United States
United States, Colorado
Colorado Springs, Colorado, United States
Denver, Colorado, United States
Golden, Colorado, United States
Loveland, Colorado, United States
United States, Connecticut
Bridgeport, Connecticut, United States
Bristol, Connecticut, United States
Norwalk, Connecticut, United States
Stamford, Connecticut, United States
Trumbull, Connecticut, United States
Waterbury, Connecticut, United States
United States, Delaware
Newark, Delaware, United States
Wilmington, Delaware, United States
United States, Florida
Aventura, Florida, United States
Boynton Beach, Florida, United States
Bradenton, Florida, United States
Brandon, Florida, United States
Brooksville, Florida, United States
Clearwater, Florida, United States
Coral Springs, Florida, United States
Daytona Beach, Florida, United States
Doral, Florida, United States
Fleming Island, Florida, United States
Fort Lauderdale, Florida, United States
Fort Myers, Florida, United States
Gainesville, Florida, United States
Green Cove Springs, Florida, United States
Hialeah, Florida, United States
Hollywood, Florida, United States
Hudson, Florida, United States
Inverness, Florida, United States
Jacksonville, Florida, United States
Lakeland, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
Ocala, Florida, United States
Oviedo, Florida, United States
Palm Beach Gardens, Florida, United States
Panama City, Florida, United States
Pembroke Pines, Florida, United States
Pensacola, Florida, United States
Plant City, Florida, United States
Plantation, Florida, United States
Ponte Vedra, Florida, United States
Port Charlotte, Florida, United States
Port Orange, Florida, United States
Rockledge, Florida, United States
Safety Harbor, Florida, United States
Saint Petersburg, Florida, United States
Sarasota, Florida, United States
South Miami, Florida, United States
Springfield, Florida, United States
St Petersburg, Florida, United States
St. Petersburg, Florida, United States
Stuart, Florida, United States
Tampa, Florida, United States
Trinity, Florida, United States
Venice, Florida, United States
Vero Beach, Florida, United States
Wellington, Florida, United States
West Palm Beach, Florida, United States
Winter Haven, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Conyers, Georgia, United States
Cumming, Georgia, United States
Marietta, Georgia, United States
Roswell, Georgia, United States
Suwanee, Georgia, United States
Tucker, Georgia, United States
United States, Illinois
Arlington Heights, Illinois, United States
Chicago, Illinois, United States
Elmhurst, Illinois, United States
Gurnee, Illinois, United States
Melrose Park, Illinois, United States
Rock Island, Illinois, United States
United States, Indiana
Anderson, Indiana, United States
Avon, Indiana, United States
Bloomington, Indiana, United States
Evansville, Indiana, United States
Franklin, Indiana, United States
Greenfield, Indiana, United States
Hammond, Indiana, United States
Indianapolis, Indiana, United States
Muncie, Indiana, United States
Munster, Indiana, United States
United States, Iowa
Iowa City, Iowa, United States
United States, Kansas
Wichita, Kansas, United States
United States, Kentucky
Louisville, Kentucky, United States
Owensboro, Kentucky, United States
United States, Maine
Auburn, Maine, United States
Bangor, Maine, United States
Biddeford, Maine, United States
Lewiston, Maine, United States
Portland, Maine, United States
United States, Maryland
Annapolis, Maryland, United States
Baltimore, Maryland, United States
Glen Burnie, Maryland, United States
Hagerstown, Maryland, United States
Hyattsville, Maryland, United States
Lutherville, Maryland, United States
Oxon Hill, Maryland, United States
Rockville, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
Fall River, Massachusetts, United States
Haverhill, Massachusetts, United States
Methuen, Massachusetts, United States
Natick, Massachusetts, United States
United States, Michigan
Alpena, Michigan, United States
Cadillac, Michigan, United States
Kalamazoo, Michigan, United States
Lapeer, Michigan, United States
Marquette, Michigan, United States
Midland, Michigan, United States
Petoskey, Michigan, United States
Rochester, Michigan, United States
Saginaw, Michigan, United States
Southfield, Michigan, United States
Traverse City, Michigan, United States
Ypsilanti, Michigan, United States
United States, Minnesota
Baxter, Minnesota, United States
Duluth, Minnesota, United States
Eagan, Minnesota, United States
Edina, Minnesota, United States
Minneapolis, Minnesota, United States
St. Paul, Minnesota, United States
United States, Mississippi
Gulfport, Mississippi, United States
Tupelo, Mississippi, United States
United States, Missouri
Chesterfield, Missouri, United States
Washington, Missouri, United States
United States, Montana
Billings, Montana, United States
Kalispell, Montana, United States
United States, Nebraska
Grand Island, Nebraska, United States
United States, Nevada
Henderson, Nevada, United States
Las Vegas, Nevada, United States
United States, New Jersey
Bridgewater, New Jersey, United States
East Brunswick, New Jersey, United States
Elmer, New Jersey, United States
Haddon Heights, New Jersey, United States
Linden, New Jersey, United States
Mine Hill, New Jersey, United States
Newark, New Jersey, United States
Sewell, New Jersey, United States
Somerset, New Jersey, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
Albany, New York, United States
Binghamton, New York, United States
Bronx, New York, United States
Buffalo, New York, United States
Endwell, New York, United States
Great Neck, New York, United States
Mineola, New York, United States
New Hyde Park, New York, United States
New York, New York, United States
North Massapequa, New York, United States
Poughkeepsie, New York, United States
Rochester, New York, United States
Southampton, New York, United States
Troy, New York, United States
Westfield, New York, United States
United States, North Carolina
Burlington, North Carolina, United States
Cary, North Carolina, United States
Charlotte, North Carolina, United States
Greensboro, North Carolina, United States
Hickory, North Carolina, United States
High Point, North Carolina, United States
Lenoir, North Carolina, United States
Morehead City, North Carolina, United States
Morganton, North Carolina, United States
Pinehurst, North Carolina, United States
Raleigh, North Carolina, United States
Rocky Mount, North Carolina, United States
Salisbury, North Carolina, United States
Sanford, North Carolina, United States
Statesville, North Carolina, United States
Wilmington, North Carolina, United States
Winston-Salem, North Carolina, United States
United States, North Dakota
Fargo, North Dakota, United States
United States, Ohio
Canton, Ohio, United States
Cincinnati, Ohio, United States
Delaware, Ohio, United States
Marion, Ohio, United States
Massillon, Ohio, United States
Springfield, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
United States, Pennsylvania
Altoona, Pennsylvania, United States
Camp Hill, Pennsylvania, United States
Danville, Pennsylvania, United States
Doylestown, Pennsylvania, United States
Duncansville, Pennsylvania, United States
Erie, Pennsylvania, United States
Feasterville, Pennsylvania, United States
Indiana, Pennsylvania, United States
Jenkintown, Pennsylvania, United States
Jersey Shore, Pennsylvania, United States
Johnstown, Pennsylvania, United States
Langhorne, Pennsylvania, United States
Lansdale, Pennsylvania, United States
Newport, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pottstown, Pennsylvania, United States
Scranton, Pennsylvania, United States
Tipton, Pennsylvania, United States
United States, Rhode Island
Cumberland, Rhode Island, United States
United States, South Carolina
Greer, South Carolina, United States
Spartanburg, South Carolina, United States
United States, South Dakota
Watertown, South Dakota, United States
United States, Tennessee
Bristol, Tennessee, United States
Chattanooga, Tennessee, United States
Greeneville, Tennessee, United States
Jackson, Tennessee, United States
Johnson City, Tennessee, United States
Kingsport, Tennessee, United States
Memphis, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Austin, Texas, United States
Carrollton, Texas, United States
Corpus Christi, Texas, United States
Dallas, Texas, United States
Fort Worth, Texas, United States
Georgetown, Texas, United States
Houston, Texas, United States
Irving, Texas, United States
Kingwood, Texas, United States
Lewisville, Texas, United States
Midland, Texas, United States
Odessa, Texas, United States
Plano, Texas, United States
Round Rock, Texas, United States
San Antonio, Texas, United States
Tomball, Texas, United States
Tyler, Texas, United States
Webster, Texas, United States
United States, Utah
Ogden, Utah, United States
Salt Lake City, Utah, United States
United States, Virginia
Alexandria, Virginia, United States
Arlington, Virginia, United States
Burke, Virginia, United States
Danville, Virginia, United States
Falls Church, Virginia, United States
Henrico, Virginia, United States
Manassas, Virginia, United States
Norfolk, Virginia, United States
Richmond, Virginia, United States
Winchester, Virginia, United States
United States, Washington
Federal Way, Washington, United States
Seattle, Washington, United States
Spokane, Washington, United States
Tacoma, Washington, United States
Wenatchee, Washington, United States
United States, Wisconsin
Green Bay, Wisconsin, United States
Kenosha, Wisconsin, United States
Madison, Wisconsin, United States
Marshfield, Wisconsin, United States
Wausau, Wisconsin, United States
Australia, New South Wales
Coffs Harbour, New South Wales, Australia
Gosford, New South Wales, Australia
Wollongong, New South Wales, Australia
Australia, Queensland
Auchenflower, Queensland, Australia
Brisbane, Queensland, Australia
Herston, Queensland, Australia
Milton, Queensland, Australia
Sherwood, Queensland, Australia
Southport, QLD, Queensland, Australia
Australia, South Australia
Adelaide, South Australia, Australia
Ashford, South Australia, Australia
Elizabeth Vale, South Australia, Australia
Fullarton, South Australia, Australia
Woodville South, South Australia, Australia
Australia, Victoria
Ballarat, Victoria, Australia
East St Kilda, Victoria, Australia
Geelong, Victoria, Australia
Heidelberg, Victoria, Australia
Australia, Western Australia
Fremantle, Western Australia, Australia
Joondalup, Western Australia, Australia
Murdoch, Western Australia, Australia
Australia
Liverpool, Australia
Bahamas
Nassau, Bahamas
Canada, Alberta
Calgary, Alberta, Canada
Canada, British Columbia
Vancouver, British Columbia, Canada
Canada, Nova Scotia
Halifax, Nova Scotia, Canada
Canada, Ontario
Brampton, Ontario, Canada
Burlington, Ontario, Canada
Cambridge, Ontario, Canada
Etobicoke, Ontario M9R 4E1 Ca, Ontario, Canada
Hamilton, Ontario, Canada
London, Ontario, Canada
Markham, Ontario, Canada
Newmarket, Ontario, Canada
Oakville, Ontario, Canada
Oshawa, Ontario, Canada
Ottawa, Ontario, Canada
Peterborough, Ontario, Canada
Sudbury, Ontario, Canada
Thornhill, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Brossard, Quebec, Canada
Gatineau, Quebec, Canada
Greenfield Park, Quebec, Canada
Levis, Quebec, Canada
Montreal, Quebec, Canada
Quebec City, Quebec, Canada
Sherbrooke, Quebec, Canada
St Jean sur Richelieu, Quebec, Canada
St-Charles-Borromee, Quebec, Canada
St-Lambert, Quebec, Canada
St-Romuald, Quebec, Canada
Ville Saint-Laurent, Quebec, Canada
Chile
Temuco, Araucania, Chile
Providencia, Santiago, Chile
San Miguel, Santiago, Chile
Concepcion, Chile
Santiago, Chile
Mexico
Guadalajara, Jalisco, Mexico
Monterrey, Nuevo Leon, Mexico
Xalapa, Veracruz, Mexico
Aguascalientes, Mexico
Distrito Federal, Mexico
New Zealand
Milford, Auckland, New Zealand
Papatoetoe, Auckland, New Zealand
Takapuna, Auckland, New Zealand
Christchurch, Canterbury, New Zealand
Dunedin, Otago, New Zealand
New Plymouth, Taranaki, New Zealand
Lower Hutt, Wellington, New Zealand
Auckland, New Zealand
Hastings, New Zealand
Nelson, New Zealand
Rotorua, New Zealand
Tauranga, New Zealand
Poland
Bezrzecze, Poland
Biala Rawska, Poland
Bialystok, Poland
Bydgoszcz, Poland
Chorzow, Poland
Chrzanow, Poland
Gdynia, Poland
Inowroclaw, Poland
Kamieniec Zabkowicki, Poland
Koluszki, Poland
Krakow, Poland
Legnica, Poland
Lodz, Poland
Lublin, Poland
Mragowo, Poland
Olsztyn, Poland
Piotrkow Trybunalski, Poland
Plock, Poland
Poznan, Poland
Szczecin, Poland
Tarnow, Poland
Teczna, Poland
Todz, Poland
Torun, Poland
Warszawa, Poland
Wierzchoslawice, Poland
Wloclawek, Poland
Wroclaw, Poland
Sponsors and Collaborators
Eisai Inc.
Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization
  More Information

Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT02019264     History of Changes
Other Study ID Numbers: APD356-G000-401  2013-000324-34 
Study First Received: December 18, 2013
Last Updated: July 15, 2016
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
Brazil: National Health Surveillance Agency
Canada: Health Canada
Chile: Comision Nacional de Investigacion Cientifica y Tecnologica
Mexico: Federal Commission for Protection Against Health Risks
New Zealand: Medsafe
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
United States: Food and Drug Administration

Keywords provided by Eisai Inc.:
Diabetes
Cardiovascular Disease
Multiple Cardiovascular Risk Factors
Obesity
Overweight
MACE
Conversion to Diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Cardiovascular Diseases
Overweight
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on July 24, 2016